latest newsRead more...
20
Feb 2019Aucta Pharmaceuticals and Oakrum Pharma Announce Product Development and Commercial Cooperation
Aucta Pharmaceuticals Inc Aucta announced today that it has entered into an agreement with Oakrum Pharma LLC Oakrum to develop and produce four A prescription generic product intended to be commercialized in the United States under the Oakrum trademark These products are expected to serve…
20
Feb 2019Exicure Announces License and Development Agreement with Dermelix Biotherapeutics in Rare Genetic Skin Diseases
Exicure Inc OTCQB XCUR the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid SNA constructs and Dermelix Biotherapeutics a biopharmaceutical company focused on the development of innovative treatments for rare genetic skin diseases today announced a license and development agreement to advance…
19
Feb 2019QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens
QIAGEN NV today announced a broad agreement with Ares Genetics a subsidiary of Curetis NV to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing global health challenges posed by antibioticresistant bacteria QIAGEN has acquired an exclusive license to leverage Ares Genetics…
19
Feb 2019WuXi STA and BioLingus sign exclusive technology and marketing collaboration for sublingual delivery
STA Pharmaceutical Co Ltd WuXi STA a subsidiary of WuXi AppTec and BioLingus a Swiss biotech company announce they have formed an exclusive technology and marketing collaboration for sublingual delivery Under the terms of the collaboration WuXi STA will have exclusive access to BioLingus technology…
press releasesRead more...
20
Feb 2019ARS Pharmaceuticals Announces FDA Fast Track Designation for ARS-1 Intranasal Epinephrine Spray
ARS Pharmaceuticals Inc a pharmaceutical company dedicated to empowering atrisk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis today announced that the US…
20
Feb 2019Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
Gamida Cell Ltd a leading cellular and immune therapeutics company today announced an agreement with Editas Medicine Inc a leading genome editing company to evaluate the potential use of Editas…
20
Feb 2019AlzProtect, on Track for a Phase 2 Entry in 2019, for its Drug Candidate AZP2006
AlzProtect a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimers disease and Progressive Supranuclear Palsy PSP announced today the successful completion of the latest phase…
20
Feb 2019Calypso Biotech BV Secures 20 Million EUR in Series A Financing and Strengthens Team to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases
Calypso Biotech an emerging leader in the development of therapeutic antibodies for autoimmune diseases announces today the closing of a M Series A financing coled by Gilde Healthcare and Inkef…
EventsRead more...
20-21
Feb 201910th Annual RNA Therapeutics Conference
SMI GROUP
Copthorne Tara Hotel
20-21
Feb 2019World Congress on Drug Discovery and Drug Design
Conference Series LLC Ltd
Holiday Inn Singapore Atrium
20-21
Feb 20193D Cell Culture 2019
SMi Group
Copthorne Tara Hotel London Kensington
20-21
Feb 201910th Annual RNA Therapeutics
SMi Group
Copthorne Tara Hotel London Kensington
TOP ARTICLES
-
1
Programmable Nanodevices for Biomedical Application: From Science Fiction to Reality
Suppose a patient is suffering from a brain tumor and immediate surgery is required to keep him alive but the location of the tumor is very critical and normal ..
-
2
Identification of MicroRNAs and Their Targets in Cancer
Although our cells are well equipped with regulatory checkpoints transformation of normal cells to malignant cancerous cells often occurs as a genetic disease W..
-
3
Smart Nano-Enabled Drug Carrier in Combating Tumor Development and Progress
Introduction The worldwide report of mortality due to lethal disease cancer is common and progressive nowadays Although nanomedicine advances in tumor biolog..
-
4
Are you Ready for EU FMD?
With the deadline looming for enactment of EU FMD and US DSCSA Vikash Pushpraj Senior Vice President rfxcel explains how achieving compliance is about much more..
-
5
Life-style, Environment, and Lack of Prediabetes Diagnosis Fueling Diabetic Epidemic
Introduction For the past ten years ample evidence exists to suggest that what we eat and how we live determines how our body and genes behave A rapid rise i..
-
6
Cancer Stem Cell (CSC) Inhibitors
Cancer as a group of heterogeneous diseases very well known Unimaginable amounts of money and manhours have been spent in finding cure for this deadly disease H..
Knowledge Bank
-
Interviews
Merck
Staff Engineer, Manufacturing Science and Technology, South East Asia
Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshoot..
-
Articles
I-MR Control Chart in Pharmaceutical Industry and the Comparison with Laney-Modified Attribute Chart: Case Study
Introduction The application of control charts in the monitoring of industrial and manufacturing processes has become an indispensable tool in the modern industry Special attention can be brought to its application in the healthcare industry However obtaining ideal results to be interpreted that fit exact conditions for dedicated types of control charts are not…
-
Research Insights
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine
Abstract Background Inflammatory breast cancer IBC is a rare aggressive form of breast cancer associated with HER amplification with high risk of metastasis and an estimated median survival of y We performed an openlabel singlearm phase II clinical trial ClinicalTrialsgov NCT to investigate the efficacy and safety of afatinib an irreversible ErbB family inhibitor alone and in combination with vinorelbine…
-
Case Studies
Rapid, Comprehensive, And Aff Ordable Mycobacterial Diagnosis With Whole-genome Sequencing: A Prospective Case Study
Abstract Background Slow and cumbersome laboratory diagnostics for Mycobacterium tuberculosis complex MTBC risk delayed treatment and poor patient outcomes Wholegenome sequencing WGS could potentially provide a rapid and comprehensive diagnostic solution In this prospective study we compare realtime WGS with routine MTBC diagnostic workflows Methods We compared…
-
Techno Trends
Nottingham University Launches First-of-its-kind Equipment for Chemical Imaging of Materials, Cells & Tissues
The University of Nottingham launched unique firstofitskind equipment DOrbiSIMS which allows labelfree chemical imaging of materials cells and tissues with the potential to transform research in these areas DOrbiSIMS will have applications in a multidisciplinary range of research areas These areas include biomedical implants drug delivery systems developing strategies to tackle antimicrobial resistance organic electronic devices and engineering applications Researchers…
-
White Papers
Launching Global Clinical Trials—best Practices For Efficient And Cost-effective Translations: A Lionsbridge White Paper
Summary The target market for conducting global clinical trials has changed significantly moving beyond pharmaceutical early adopters to the mainstream marketplace This shift has placed a heightened focus on the language challenges and complexity of running a global clinical trial More and more companies are moving toward ascending regions such as India and China to…
Advisory Board
Editorial Section
-
Strategy
WAYS TO CREATE MORE AND MORE CONSISTENT PERFORMERS
For all pharma businesses it is a challenge to enable their field forceSales and Marketingto be consistent performers The success or failure in this direction will accordingly decide the fate of the organisations Even if an organisation has highly innovative…
-
Research development
New and Novel Drug Delivery Technologies
By infusing drugs with new and innovative therapeutic benefits drug delivery systems extend products profitable lifecycle giving pharmaceutical companies competitive and financial advantages and providing patients with improved medications Formulation development is being used in the creation of new dosage…
-
Clinical Trials
ELIXIR FOR SOURCING AND RETAINING CANDIDATES
Many pharma companies have been suffering silently from shortage of suitable candidates to fill up vacancies in the field and also of high attrition rate leading to terrible but avoidable loss of business due to vacancies In this article lets…
-
Manufacturing
CLINICAL MANUFACTURING ON TIME AND WITHIN BUDGET
In a record submitted drugs received approval from the American regulatory agency FDA One of the reasons for this success is the reciprocal commitment between the sponsor and regulatory bodies to maintain a high quality…
-
Information Technology
Creating Better Clean Label Soft Gels Without Gelatin Crosslinking
Modern manufacturers are facing to produce the perfect clean label soft gel Crosslinking is a common reaction in gelatin capsules with a direct impact on APIs bio availability and opening time Modern technology offers a…
-
Expert Talk
The Pharmaceutical Supply Chain from a CDMO’s Perspective
In the world of drug manufacturing change is a constant In order to be successful Contract Development and Manufacturing Organisations CDMOs must remain flexible anticipating and adjusting to market dynamics as necessary This ability to…
